Smoking Linked to Cognitive Decline in Children: Study

Aug.31.2022
Smoking Linked to Cognitive Decline in Children: Study
Smoking linked to poor cognitive performance and brain volume reduction in children, per a 2-year study on 1000+ children in Nebraska, US.

A study conducted in the state of Nebraska, United States revealed that smoking is associated with poor cognitive performance and reduced brain volume among more than 1,000 children aged 9 to 10 years old who were followed up for two years. The study found that the effects of smoking could have a lasting impact.


Among those investigated, 116 children reported using tobacco products and were considered to be the earliest group of tobacco users in the study. This group performed poorly on the tests (mean, b = -2.9; SE, 0.6; P <.001), showing lower crystallized cognitive composite scores (b = -2.4; SE, 0.5; P <.001) and total cognitive composite scores (b = -2.9; SE, 0.5; P = .01). In a follow-up study of two years, smokers had lower cortical volumes in the frontal, parietal, and temporal lobes than non-users.


According to a report by Dr. Hongying Daisy Dai, Chief Researcher at the University of Nebraska Medical Center, electronic cigarettes and smokeless tobacco products should not be considered as a substitute to traditional cigarettes for youth to reduce tobacco-related harm. Authorities should implement comprehensive intervention strategies and tobacco control policies to prevent tobacco initiation.


From October 2016 to October 2018, a study titled Adolescent Brain Cognitive Development (ABCD) included 11,729 children from 21 US-based websites. This study followed up with the participants from August 2018 to January 2021. Participants were asked to complete a survey about tobacco use, including e-cigarettes, cigarettes, cigars, smokeless tobacco, hookah, pipes, and nicotine replacement products.


Dai and colleagues utilized a comprehensive combination of cognitive assessment measures, including the National Institutes of Health Toolbox Cognitive Battery, morphometric analysis, and structural MRI, to evaluate differences between users and non-users. In terms of race and ethnicity, 2.1% of the sample were Asian; 20.3% were Hispanic/Latino; 14.9% were non-Hispanic Black; and 52.1% were non-Hispanic White. Just over a quarter (27.3%) of the sample had parents who were college graduates, and 13.7% had parents with an annual income less than $25,000.


During a two-year follow-up period, the scores of first-time tobacco users in oral recognition (b=-2.1; SE, 0.5; P<.001), picture sequencing memory (b=-3.0; SE, 0.7; P<.001), and crystallized cognitive composite scores (b=-2.7; SE, 0.8; P=.005) remained lower than non-users. In SMRI analysis, former smokers exhibited significantly decreased measurements in the entire brain, including the total cortical surface area in the first wave (b=-5014.8 mm3; SE, 7043.9; P=.002), total cortical volume in the first wave (b=-174,621.0 mm3; SE, 5857.7; P=.003) and follow-up (b=-21,790.8 mm3; SE, 7043.9; P=.002), and total intracranial volume in the first wave (b=-38,442.8 mm3; SE, 12,057.7; P=.009).


In a related editorial, Dr. Laviolette from the University of Western Ontario wrote, "The findings reported by Dai and colleagues raise many important questions for future clinical and preclinical investigations. It is important to determine the extent to which these pathophysiological findings extend beyond the window of brain maturation prior to adolescence. Furthermore, it is crucial to identify the specific molecular mechanisms and biomarkers underlying these persistent tobacco-induced pathophysiological effects.


He added that the description of potential mechanisms could facilitate similar identification of intervention and reversal strategies for "neurological and psychiatric phenotypes caused by nicotine exposure in children, adolescents, and even prenatal exposure." Additionally, advances in genomic and transcriptomic analysis could better understand the potential genetic factors that could make individuals more susceptible to nicotine products during critical periods of brain development, as well as factors that could increase the risk of serious neurological and cognitive outcomes after exposure to nicotine during the developmental window for some individuals.


Statement: 1. This article's content is based on the compilation of third-party information and is intended solely for industry exchanges and learning purposes. 2. The views expressed in this article do not represent those of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The compilation of this article is for industry exchange and research purposes only. 3. Due to limited compilation skills, the translated article may not fully reflect the original text. Please refer to the original text for accuracy. 4. Regarding any domestic, Hong Kong, Macao, Taiwan, or international statements or positions, 2FIRSTS is fully aligned with the Chinese government. 5. The copyright of the compiled information belongs to the original media and author. Please contact us for removal if there are any infringements.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
The U.S. Court of Appeals for the Ninth Circuit upheld the FDA’s denial of MH Global LLC’s applications to market flavored electronic nicotine delivery systems (ENDS). The court ruled that FDA’s comparative-efficacy framework, which requires applicants to show that flavored products provide greater cessation or switching benefits than tobacco-flavored alternatives, is consistent with the Tobacco Control Act’s “appropriate for the protection of the public health” standard. The court also found that FDA was not required to establish the framework through notice-and-comment rulemaking.
Aug.26
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
Philippines BIR Steps Up Illicit Vape Enforcement Ahead of Christmas Shopping
Philippines BIR Steps Up Illicit Vape Enforcement Ahead of Christmas Shopping
The Philippines’ Bureau of Internal Revenue is intensifying enforcement against illicit vape and tobacco products ahead of the Christmas shopping season, directing regional and enforcement offices to strengthen monitoring of production sites, warehouses, distribution channels and retail outlets. The BIR destroyed 240,550 illicit vape products in August with an estimated tax liability of about PHP1.53 billion. A nationwide tax-compliance operation in July also inspected 3,590 businesses involved in tobacco and vapor products.
Regulations
Sep.17 by 2Firsts Perspectives
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands has agreed to acquire 100% of Swedish modern oral nicotine company Yoik Group AB for an initial SEK515 million, equivalent to about US$53.9 million, plus a deferred payment linked to performance over the next two years. Yoik owns nicotine pouch brand Helwit, which held about 3.4% of Sweden’s modern oral nicotine market over the past 12 months. Imperial says the acquisition will more than double its existing share of the Swedish market. Helwit is also sold elsewhere in the Nordics, through European online channels and in selected UK retail outlets.
Sep.08
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20
Philippines Weighs Unified Vape Tax as Lawmakers Back Risk-Based Rates and Government Seeks to Fill ₱66 Billion Revenue Gap
Philippines Weighs Unified Vape Tax as Lawmakers Back Risk-Based Rates and Government Seeks to Fill ₱66 Billion Revenue Gap
Philippine lawmakers are considering an overhaul of the country's vape excise-tax regime to eliminate the wide gap between taxes on nicotine salt and freebase nicotine liquids and reduce incentives for misdeclaration. House Bill 5364, filed by Rep. Rufus Rodriguez and Rep. Maximo Rodriguez Jr., would impose a unified ₱10-per-milliliter tax on vapor products, with 5% annual increases beginning in 2027. Rodriguez says the proposal could generate an average ₱6 billion in annual collections from 2027 through 2030. The debate comes as the Philippine government considers tobacco, vape and other health-tax reforms to help offset around ₱66 billion in revenue expected to be forgone under a proposed tax-relief package.
Aug.18